A US listing for the oncology specialist continues a bumper year for biotech IPOs.

ADC Therapeutics' restructuring extends cash runway to 2029, but Zynlonta safety/regulatory risks loom. Click here to read ...

For almost a century the media stood as the “Fourth Estate,” charged with keeping governments honest by exposing what those ...

Novartis exercises option to acquire Sironax’s brain delivery platform Sironax to advance three clinical-stage programs and multiple early-stage ...

BIAF announces closing of $4 million registered direct financing of common stock and private placement priced at-the-market ...

Iambic Therapeutics is aiming for a $135 million IPO in net proceeds as the AI biotech looks to fund the clinical development ...

MacroGenics (US5560991094) had senior executive Ezio Bonvini exercise 8,000 options on October 6, 2026 at USD 2.60 per share, ...

In the third article of the series, Matteo Tardelli explains how to present academic experience in a way that appeals to ...

Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven ...

Overall, combining a low-energy diet with structured aerobic and resistance exercise achieved substantial remission in ...

In connection with the Rights Issue, 38,979,790 warrants of series TO 2 were issued. Each warrant of series TO 2 entitles the holder to subscribe for one (1) new share in Bio-Works at a subscription ...

A Bullish Biotech Funding Market and a Higher Bar for Companies Seeking Capital - Importance of milestone-based development ...